Study Name:
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Targeted Disease(s):
Lung Cancer
Purpose of Study:
The purpose of this study is to assess the safety profile of nivolumab plus relatlimab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves progression free survival (PFS) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell LUNG CANCER (NSCLC).
Study Dates:
November 30, 2020 - July 1, 2026
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Bristol Myers Squibb
Sponsors:
Bristol Myers Squibb
Contact:
BMS Study Connect
855-907-3286
Clinical.Trials@bms.com
ClinicalTrails.gov Identifier:
NCT04623775
